CASTLE BIOSCIENCES INC (CSTL) Stock Overview
NASDAQ:CSTL - US14843C1053 - Common Stock
CSTL Key Statistics, Chart & Performance
The current stock price of CSTL is 20.84 USD. In the past month the price increased by 29.68%. In the past year, price decreased by -29.52%.
CSTL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.25 | 90.20B | ||
| CI | THE CIGNA GROUP | 10.83 | 81.24B | ||
| LH | LABCORP HOLDINGS INC | 18.37 | 23.12B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.05 | 20.15B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 116.22 | 15.17B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 12.61 | 15.02B | ||
| DVA | DAVITA INC | 14.49 | 10.60B | ||
| HIMS | HIMS & HERS HEALTH INC | 55.71 | 9.98B | ||
| GH | GUARDANT HEALTH INC | N/A | 7.66B | ||
| CHE | CHEMED CORP | 20.52 | 6.72B | ||
| RDNT | RADNET INC | 194.72 | 5.39B | ||
| CRVL | CORVEL CORP | 50.9 | 4.75B |
Related stock screener links
About CSTL
Company Profile
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 761 full-time employees. The company went IPO on 2019-07-25. The Company’s portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-Melanoma is its risk stratification gene expression profile (GEP) test that predicts the likelihood of positive sentinel lymph node and the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM). DecisionDx-SCC is its GEP test for use in patients with cutaneous squamous cell carcinoma (SCC).
Company Info
CASTLE BIOSCIENCES INC
505 S Friendswood Drive, Suite 401
Friendswood TEXAS 77546 US
CEO: Derek J. Maetzold
Employees: 761
Phone: 18667889007
CASTLE BIOSCIENCES INC / CSTL FAQ
What is the stock price of CASTLE BIOSCIENCES INC today?
The current stock price of CSTL is 20.84 USD. The price increased by 4.36% in the last trading session.
What is the ticker symbol for CASTLE BIOSCIENCES INC stock?
The exchange symbol of CASTLE BIOSCIENCES INC is CSTL and it is listed on the Nasdaq exchange.
On which exchange is CSTL stock listed?
CSTL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CASTLE BIOSCIENCES INC stock?
15 analysts have analysed CSTL and the average price target is 36.83 USD. This implies a price increase of 76.74% is expected in the next year compared to the current price of 20.84. Check the CASTLE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CASTLE BIOSCIENCES INC worth?
CASTLE BIOSCIENCES INC (CSTL) has a market capitalization of 604.57M USD. This makes CSTL a Small Cap stock.
How many employees does CASTLE BIOSCIENCES INC have?
CASTLE BIOSCIENCES INC (CSTL) currently has 761 employees.
What are the support and resistance levels for CASTLE BIOSCIENCES INC (CSTL) stock?
CASTLE BIOSCIENCES INC (CSTL) has a support level at 19.89 and a resistance level at 20.85. Check the full technical report for a detailed analysis of CSTL support and resistance levels.
Is CASTLE BIOSCIENCES INC (CSTL) expected to grow?
The Revenue of CASTLE BIOSCIENCES INC (CSTL) is expected to decline by -10.26% in the next year. Check the estimates tab for more information on the CSTL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CASTLE BIOSCIENCES INC (CSTL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CSTL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CSTL, evaluating the profitability, health, valuation and growth aspects
- CASTLE BIOSCIENCES INC (CSTL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CASTLE BIOSCIENCES INC (CSTL) Sales and EPS estimates to see what analysts future expectations are.
- CASTLE BIOSCIENCES INC (CSTL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CASTLE BIOSCIENCES INC (CSTL) Insider and Institutional Ownership to learn about the owners and their transactions.
- CASTLE BIOSCIENCES INC (CSTL) Stock Chart to make your own analysis
- CASTLE BIOSCIENCES INC (CSTL) Latest news and press-releases to stay up to date.
Does CASTLE BIOSCIENCES INC (CSTL) stock pay dividends?
CSTL does not pay a dividend.
When does CASTLE BIOSCIENCES INC (CSTL) report earnings?
CASTLE BIOSCIENCES INC (CSTL) will report earnings on 2025-11-03, after the market close.
What is the Price/Earnings (PE) ratio of CASTLE BIOSCIENCES INC (CSTL)?
The PE ratio for CASTLE BIOSCIENCES INC (CSTL) is 57.89. This is based on the reported non-GAAP earnings per share of 0.36 and the current share price of 20.84 USD. Check the full fundamental report for a full analysis of the valuation metrics for CSTL.
What is the Short Interest ratio of CASTLE BIOSCIENCES INC (CSTL) stock?
The outstanding short interest for CASTLE BIOSCIENCES INC (CSTL) is 4.98% of its float. Check the ownership tab for more information on the CSTL short interest.
CSTL Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CSTL. When comparing the yearly performance of all stocks, CSTL is a bad performer in the overall market: 69.3% of all stocks are doing better.
CSTL Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CSTL. While CSTL has a great health rating, there are worries on its profitability.
CSTL Financial Highlights
Over the last trailing twelve months CSTL reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS increased by 357.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.74% | ||
| ROE | -2.08% | ||
| Debt/Equity | 0.02 |
CSTL Forecast & Estimates
15 analysts have analysed CSTL and the average price target is 36.83 USD. This implies a price increase of 76.74% is expected in the next year compared to the current price of 20.84.
For the next year, analysts expect an EPS growth of -485.74% and a revenue growth -10.26% for CSTL